Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05179460 · ClinicalTrials.gov registry record
A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy
A clinical trial, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 2
- Enrollment target
NCT05179460 is a clinical trial that has completed, run by Janssen Research & Development. The registered enrollment target is 2 participants.
The verdict
NCT05179460 has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate incidence and prevalence rates of the study endpoints (pigmentary maculopathy \[PM\]/ pigmentary retinopathy \[PR\]/Any, PM/PR/ pentosan polysulfate sodium \[PPS\], and PM/PR/Non-PPS) in relation to PPS exposure, and in participants with interstitial cystitis (IC) but not exposed to PPS; changes in visual acuity (VA) over time; participant treatment journey leading to PPS treatment, and potential risk factors associated with the occurrence of PM/PR/PPS.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-10-26 |
| Est. Completion | 2022-05-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05179460
The ClinicalTrials.gov registry entry for NCT05179460 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05179460 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05179460 about?
NCT05179460 is a clinical study titled "A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy". The purpose of this study is to evaluate incidence and prevalence rates of the study endpoints (pigmentary maculopathy \[PM\]/ pigmentary retinopathy \[PR\]/Any, PM/PR/ pentosan polysulfate sodium \[PPS\], and PM/PR/Non-PPS) in relation to PPS exposure, and in participants with interstitial cystitis...
What is the current status of trial NCT05179460?
This trial is currently completed. The enrollment target is 2 participants. The study started on 2021-10-26. Estimated completion is 2022-05-20.
Who is sponsoring clinical trial NCT05179460?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.